Invivyd, Inc. - Common Stock, $0.0001 par value per share (IVVD)

CUSIP: 00534A102

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class
Equity / Common Stock, $0.0001 par value per share
Total 13F shares
240,166,025
Total 13F value
$593,700,240
Holder snapshot 6 visible 7 signals
Share change
+102,672,185
Put/Call ratio
59%
SEC-reported price per share
$2.47
Number of holders
115
Value change
+$254,574,063
Number of buys
73
Open additional details 1 more signal available
Number of sells
24
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
304,892,029

Security key

00534A102

Report period

Q4 2025

Institutions

115

Top holders

10

IVVD full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Invivyd, Inc. SEC filings Invivyd, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of IVVD - Invivyd, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
Adimab, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F 13D/G 3/4/5 Lead comparable stake: 12% 13D/G row: JANUS HENDERSON GROUP PLC Showing 1-6 of 15 holder rows.

Quick read

JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 12%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership Top 5
JANUS HENDERSON GROUP PLC 12%
BIOTECHNOLOGY VALUE FUND L P 9%
PERCEPTIVE ADVISORS LLC 7.9%
Adimab, LLC 7.3%
MAVERICK CAPITAL LTD 6.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
JANUS HENDERSON GROUP PLC
13F 13D/G
Company
13F 13D/G
12%
from 13D/G
$28,048,300
25,383,077 shares
 — 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
13D/G
9%
$64,323,000
25,525,000 shares
 +$24,003,000 31 Dec 2025
PERCEPTIVE ADVISORS LLC
13D/G
13D/G
7.9%
$40,738,260
21,785,166 shares
 $0 18 Nov 2025
Adimab, LLC
3/4/5 13D/G
10%+ Owner
3/4/5 13D/G
7.3%
from 13D/G
$85,667,229
21,687,906 shares
 — 19 Jan 2024
MAVERICK CAPITAL LTD
13D/G 13F
Company
13D/G 13F
6.7%
$47,806,701
18,970,913 shares
 +$22,029,323 31 Dec 2025
MITHRIL II LP
3/4/5 13D/G
Other*, 10%+ Owner
3/4/5 13D/G
4.8%
from 13D/G
$44,404,241
11,241,580 shares
 — 28 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
115
Shares
240,166,025
Rows available
115
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
77
Q4 2025 holders
115
Holder diff
38
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .